Assessment of insulin-releasing and glucose-lowering effects of Piper guineense extracts in cellular and animal models of type 2 diabetes

Opeolu Ojo; Mojisola Adie; Simren Heer; John Edeani; Ayokunle Falana; Ayodele Falobi; Constance Ojo

doi:10.1530/endoabs.110.P347

P347

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 P347 | DOI: 10.1530/endoabs.110.P347

ECEESPE2025 Poster Presentations Diabetes and Insulin (143 abstracts)

Assessment of insulin-releasing and glucose-lowering effects of Piper guineense extracts in cellular and animal models of type 2 diabetes

Opeolu Ojo ¹ , 2 , Mojisola Adie ¹ , Simren Heer ¹ , John Edeani ¹ , Ayokunle Falana ¹ , Ayodele Falobi ¹ & Constance Ojo ³

Author affiliations

¹University of Wolverhampton, UK, Diabetes Research Group, Research Institute in Healthcare Sciences, School of Life Sciences, Wolverhampton, United Kingdom; ²IRiD Biosciences, Stokes-on-Trent, United Kingdom; ³University of Wolverhampton, UK, School of Engineering, Wolverhampton, United Kingdom

JOINT2641

Aim: Piper guineense is a plant used traditionally for the management of diabetes in many countries across West Africa. However, mechanisms underlying its actions are poorly understood. This study assessed phytochemical composition, insulin-releasing effects of aqueous extracts of the plant extract

Methods: The screening for common flavonoids and phenolic compounds in P. guineense was carried out. Actions of P. guineense extracts (0–1000µg/ml) on insulin release, cell viability and markers of cytotoxicity in BRIN-BD11 cells and in mice fed with a high-fat diet were assessed. The involvement of the ATP-dependent pathway in the actions of the plant extract was also assessed.

Results: Aqueous extract of P. guineense had total phenolic and flavonoids content of 1. 84±0. 18GE/g and 1. 72±0. 16QE/g respectively. The extract stimulated non-toxic insulin release from BRIN-BD11 cells at all concentrations tested (0. 01 – 1000µg/ml, 1. 2- to 2. 3-fold, P < 0. 05 to P < 0. 001). The observed insulinotropic effects was glucose-dependent (1. 8-fold, P < 0. 001 at 1. 1mM to 5. 6mM; 1. 5-fold, P < 0. 01 at 5. 6mM to 16. 7mM). Effects of P. guineense increased in the presence of KCl (30mM, 1. 5-fold, P < 0. 01). Reduced effects were observed in the presence of verapamil (50nM, 43%, P < 0. 001), diazoxide (300µM, 53%, P < 0. 001) and absence of extracellular calcium (48%, P < 0. 01). P. guineense improved glucose tolerance (24. 7 – 38. 4%, P < 0. 01-0. 001 at 150 - 300mg/kg bw) and plasma insulin levels (1. 6 - 2. 8-fold, P < 0. 01 at 150 - 300mg/kg bw) in high fat fed mice in a dose-dependent manner.

Conclusions: Observed anti-diabetic actions provide a basis for further research of the therapeutic potential of P. guineense extract as an anti-diabetic agent.